Showing 4581-4590 of 5623 results for "".
- Optos Introduces Ultra-Widefield Imaging Advancementshttps://modernod.com/news/optos-introduces-ultra-widefield-imaging-advancements/2478659/Optos has announced the introduction of several advancements to its Ultra-Widefield (UWF) imaging devices. The Optos platform, which includes Daytona, California, Monaco, and Silverstone, is the only retinal imaging t
- Palatin Technologies Announces Positive Results From its Phase 2 Study of PL9643 in Patients With Dry Eye Diseasehttps://modernod.com/news/palatin-technologies-announces-positive-results-from-its-phase-2-study-of-pl9643-in-patients-with-dry-eye-disease/2478661/Palatin Technologies announced positive results in its phase 2 study of PL9643 for the treatment of dry eye disease (DED). Statistically significant improvement in multiple signs and symptoms was achieved in the moderate to severe patient population after 2 weeks of dosing and at the 12-week visi
- FDA Panel Endorses Pfizer, BioNTech’s COVID-19 Vaccinehttps://modernod.com/news/fda-panel-endorses-pfizer-biontechs-covid-19-vaccine/2478650/An FDA advisory panel that convened Thursday to discuss Pfizer and BioNTech’s COVID-19 vaccine BNT162b2 voted 17-4, with one abstention, in favor of authorizing it for emergency use in people 16 years and older. The vote follows the release of briefing documents earlier this week in which F
- Regenxbio Announces Dosing of First Patient in Phase 2 ALTITUDE Trial of RGX-314 for the Treatment of DRhttps://modernod.com/news/regenxbio-announces-dosing-of-first-patient-in-phase-2-altitude-trial-of-rgx-314-for-the-treatment-of-dr/2478651/Regenxbio announced that the first patient has been dosed in ALTITUDE, a phase 2 trial to evaluate the suprachoroidal delivery of RGX-314 using the SCS Microinjector for the treatment of diabetic retinopathy (DR). “We are pleased to announce the first patient dosed in our ALTITUDE tr
- Alsanza Announces Global Launch of Alsee Zero Glistening, Zero Haze Hydrophobic Monofocal IOLhttps://modernod.com/news/alsanza-globally-launches-zero-glistening-zero-haze-hydrophobic-monofocal-iol-alsee/2478652/Germany-based Alsanza announced the launch of the Alsee Zero Glistening Zero Haze Hydrophobic Monofocal IOL. The Alsee IOL is developed and designed to provide long-term clarity and high-contrast sensitive quality of vision with its 24-hour aspheric optic design. Alsee Zero Glistening Zero
- No Red Flags in FDA Review of Pfizer, BioNTech’s COVID-19 Vaccine Candidatehttps://modernod.com/news/no-red-flags-in-fda-review-of-pfizer-biontechs-covid-19-vaccine-candidate/2478641/In briefing documents released Tuesday ahead of an FDA advisory committee meeting on December 10, agency staff said that efficacy data submitted by Pfizer and BioNTech in support of BNT162b2 are “consistent” with recommendations previously detailed in guidance on the emergency-use aut
- Norlase Announces Newly Appointed Distributors into Major European Marketshttps://modernod.com/news/norlase-announces-newly-appointed-distributors-into-major-european-markets/2478640/Norlase has announced new distributor partnerships developed to advance market growth and global expansion of the Norlase family of green laser systems into France, Germany, Italy, Spain, and the United Kingdom. “We’re thrilled to announce that most ophthalmologists in Europe will no
- Aldeyra Announces First Patient Enrolled in the Phase 3 TRANQUILITY Trial of Reproxalap for the Treatment of Dry Eye Diseasehttps://modernod.com/news/aldeyra-announces-first-patient-enrolled-in-the-phase-3-tranquility-trial-of-reproxalap-for-the-treatment-of-dry-eye-disease/2478638/Aldeyra Therapeutics announced enrollment of the first patient in the phase 3 TRANQUILITY trial of 0.25% reproxalap ophthalmic solution for the treatment of dry eye disease. The multicenter randomized, double-masked, parallel design, vehicle-controlled clinical trial will assess the effica
- Novaliq Announces First Patient Randomized in the ESSENCE-2 Phase 3 Trial of Dry Eye Treatment CyclASolhttps://modernod.com/news/novaliq-announces-first-patient-randomized-in-the-phase-3-trial-essence-2-of-dry-eye-treatment-cyclasol/2478637/Novaliq announced that it has initiated the randomization of patients in its phase 3 clinical trial ESSENCE-2 that is designed to replicate efficacy results of the previous phase 2/3 ESSENCE-1 trial. “The initiation of this second registrational trial represents a key milestone for b
- Tilak Healthcare Partners With Novartis to Promote Mobile App OdySighthttps://modernod.com/news/tilak-healthcare-partners-with-novartis-in-ophthalmology/2478634/Tilak Healthcare, a provider of digital therapeutics, has announced an agreement with Novartis Pharma for the promotion internationally of OdySight, Tilak Healthcare’s first clinically validated mobile app for patient remote vision monitoring. Financial terms of the deal were not disclosed